Strata Skin SciencesFRA:E2O 38 EBITDA Margin % is 15.72% as of Dec. 2025, which is 255% above its 10-year median of 4.43. GuruFocus rates FRA:E2O with a GF Score™ of 38/100 and a GF Value™ of €56.54. The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Strata Skin Sciences ranks worse than 61.4% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Strata Skin Sciences EBITDA Margin % Related Terms
Strata Skin Sciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Strata Skin Sciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:E2O vs IRME, NUMD, WOK: EBITDA Margin % Comparison
For the Medical Devices subindustry, Strata Skin Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Skin Sciences EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Strata Skin Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strata Skin Sciences (FRA:E2O) has a EBITDA Margin % of 15.72% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Strata Skin Sciences and its competitors. This is 255% above median its historical median of 4.43. According to the industry distribution chart, Strata Skin Sciences ranks #501 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 61.4%.
Is Strata Skin Sciences' EBITDA Margin % too high?
Strata Skin Sciences' current EBITDA Margin % of 15.72% is 255% above median its 10-year median of 4.43. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Strata Skin Sciences' value of 15.72% is 110.3% above this industry median. Based on the distribution chart, Strata Skin Sciences ranks #501 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Strata Skin Sciences' EBITDA Margin % compare to IRME and NUMD?
According to the Medical Devices & Instruments industry distribution chart, Strata Skin Sciences ranks #501 out of 816 companies for EBITDA Margin %. This places Strata Skin Sciences in the lower half of its industry. The industry median EBITDA Margin % is 7.48. Strata Skin Sciences' value of 15.72% is 110.3% above this benchmark. While the company's 10-year median is 4.43 vs. the industry median of 7.48, Strata Skin Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Strata Skin Sciences's current EBITDA Margin % of 15.72% is 110.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Strata Skin Sciences and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Strata Skin Sciences's current EBITDA Margin % is 15.72%, which is 255% above median its own 10-year median of 4.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Strata Skin Sciences (FRA:E2O) has a current EBITDA Margin % of 15.72%. The stock's GF Value™ is €56.54, compared to a current price of €3.76 — trading 93.3% below its estimated fair value. The current EBITDA Margin % is 15.72%, which is 255% above median its 10-year median of 4.43 and 110.3% above the Medical Devices & Instruments industry median of 7.48. Strata Skin Sciences' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current EBITDA Margin % is 15.72% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued.
The current stock price of €3.76 is trading 93.3% below its estimated GF Value™ of €56.54.
Key valuation signals for FRA:E2O:
EBITDA Margin %: 15.72% (255% above median its 10-year median of 4.43)
GF Value™: €56.54 vs. price of €3.76 (93.3% below fair value)
Industry Position: 110.3% above the Medical Devices & Instruments median (#501 of 816)
No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
38GF Score
Get the complete analysis for FRA:E2O
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:E2O has been successfully added to your 
